Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

KRRO

Korro Bio Inc.

Sep 06 • 04:00PM ET

40.80

Dollar change -1.93
Percentage change -4.52	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN VTWO VHT IWO IWC ITOT VTWV

Index	RUT	P/E	-	EPS (ttm)	-25.49	Insider Own	36.47%	Shs Outstand	8.02M	Perf Week	-18.33%
Market Cap	379.44M	Forward P/E	-	EPS next Y	-9.79	Insider Trans	5.56%	Shs Float	5.91M	Perf Month	14.83%
Income	-92.22M	PEG	-	EPS next Q	-2.55	Inst Own	62.88%	Short Float	4.99%	Perf Quarter	-8.81%
Sales	0.00M	P/S	-	EPS this Y	82.24%	Inst Trans	-28.19%	Short Ratio	3.43	Perf Half Y	-16.87%
Book/sh	21.34	P/B	1.91	EPS next Y	-3.86%	ROA	-56.06%	Short Interest	0.29M	Perf Year	263.47%
Cash/sh	17.12	P/C	2.38	EPS next 5Y	-	ROE	-75.75%	52W Range	4.57 - 97.91	Perf YTD	-14.88%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-11.67%	ROI	-39.06%	52W High	-58.33%	Beta	3.86
Dividend TTM	-	Quick Ratio	13.28	Sales past 5Y	-26.84%	Gross Margin	-	52W Low	791.80%	ATR (14)	4.48
Dividend Ex-Date	-	Current Ratio	13.28	EPS Y/Y TTM	73.20%	Oper. Margin	0.00%	RSI (14)	42.90	Volatility	11.34% 11.52%
Employees	101	Debt/Eq	0.19	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	123.75
Option/Short	No / Yes	LT Debt/Eq	0.19	EPS Q/Q	83.89%	Payout	-	Rel Volume	0.41	Prev Close	42.73
Sales Surprise	-	EPS Surprise	-0.06%	Sales Q/Q	-	Earnings	Aug 13 AMC	Avg Volume	85.92K	Price	40.80
SMA20	-6.03%	SMA50	-5.39%	SMA200	-20.40%	Trades		Volume	35,021	Change	-4.52%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-14-24	Initiated	William Blair	Outperform	$180
Mar-28-24	Reiterated	H.C. Wainwright	Buy	$100 → $115
Feb-27-24	Initiated	BMO Capital Markets	Outperform	$120
Dec-04-23	Initiated	H.C. Wainwright	Buy	$100
Nov-29-23	Initiated	RBC Capital Mkts	Outperform	$70
Nov-10-23	Initiated	Piper Sandler	Overweight	$180
Feb-15-23	Downgrade	Chardan Capital Markets	Buy → Neutral
Feb-13-23	Downgrade	Cowen	Outperform → Market Perform
Sep-22-21	Downgrade	Goldman	Buy → Neutral	$12 → $9
Jan-27-21	Upgrade	JP Morgan	Neutral → Overweight	$56
Dec-22-20	Initiated	B. Riley Securities	Buy	$79
Jul-14-20	Initiated	Oppenheimer	Outperform	$36
May-18-20	Downgrade	JP Morgan	Overweight → Neutral	$27
Oct-28-19	Initiated	JP Morgan	Overweight	$25
Oct-28-19	Initiated	Goldman	Buy	$30
Oct-28-19	Initiated	Cowen	Outperform

Show Previous Ratings

Aug-28-24 08:00AM	Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors (GlobeNewswire)
Aug-27-24 08:00AM	Korro to Participate in Upcoming September Investor and Scientific Conferences (GlobeNewswire)
Aug-13-24 04:01PM	Korro Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) +9.21%
Jul-01-24 08:00AM	Korro Joins the Russell 2000 , Russell 3000 , and Russell Microcap Indexes (GlobeNewswire)
Jun-25-24 12:53PM	KRRO Stock Earnings: Korro Bio Beats EPS for Q4 2023 (InvestorPlace)
04:01PM	Loading…
May-30-24 04:01PM	Korro to Participate in Upcoming June Investor and Scientific Conferences (GlobeNewswire)
May-20-24 02:30PM	Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference (GlobeNewswire)
May-14-24 10:55PM	KRRO Stock Earnings: Korro Bio Beats EPS for Q1 2024 (InvestorPlace) +5.43%
04:01PM	Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer (GlobeNewswire)
Apr-18-24 08:30AM	Korro Announces $70 Million Private Placement (GlobeNewswire)
Apr-01-24 04:01PM	Korro to Participate in Upcoming Investor Conferences (GlobeNewswire) -7.90%
Mar-26-24 04:01PM	Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress (GlobeNewswire) +18.43%
Feb-27-24 09:55AM	Wall Street Analysts Believe Korro Bio, Inc. (KRRO) Could Rally 86.94%: Here's is How to Trade (Zacks) -6.08%
08:00AM	Korro to Present at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-09-24 09:55AM	Does Korro Bio, Inc. (KRRO) Have the Potential to Rally 59.66% as Wall Street Analysts Expect? (Zacks)
08:00AM	Loading…
Jan-18-24 08:00AM	Korro Bio Highlights Data for its Lead Program in Alpha-1 Antitrypsin Deficiency (AATD) and Progress Across its RNA Editing Portfolio (GlobeNewswire) -5.98%
Jan-04-24 08:00AM	Korro to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-07-23 08:00AM	Korro Announces Selection of its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire) -14.67%
Nov-28-23 08:00AM	Korro Bio Appoints Dr. Rachel Meyers to Board of Directors (GlobeNewswire) +6.45%
Nov-03-23 03:31PM	UPDATE: Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million (GlobeNewswire) +5.94%
12:19PM	Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million (GlobeNewswire)
Aug-10-23 04:01PM	Frequency Therapeutics Provides Business Updates and Second Quarter 2023 Financial Results (Business Wire)
Jul-17-23 11:59AM	Frequency (FREQ) Up 77% on Merger Deal With Korro Bio (Zacks) -12.66%
Jul-14-23 11:22AM	Why Are Frequency Therapeutics Shares Surging Today (Benzinga) +77.47%
06:30AM	Korro Bio and Frequency Therapeutics Announce Merger Agreement (Business Wire)
May-12-23 04:01PM	Frequency Therapeutics Provides Business Updates and First Quarter 2023 Financial Results (Business Wire) -5.17%
Mar-10-23 07:30AM	Frequency Therapeutics Provides Business Updates and Fourth Quarter and Full Year 2022 Financial Results (Business Wire)
Feb-27-23 07:30AM	Frequency Therapeutics to Participate at Upcoming March Investor Conferences (Business Wire) +5.40%
Feb-13-23 01:55PM	Hearing loss startup to cut more than half of staff in wake of trial failure (American City Business Journals) -80.54%
11:17AM	Frequency Therapeutics' Lead Hearing Loss Program Flunks, Shifts Focus To Multiple Sclerosis, Shares Plunge (Benzinga)
08:05AM	Loading…
08:05AM	Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss (Business Wire)
Dec-19-22 07:30AM	Frequency Therapeutics Announces Formation of Clinical Advisory Board for Remyelination in Multiple Sclerosis Program (Business Wire)
Dec-15-22 07:30AM	Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Companys Second Therapeutic Candidate for Sensorineural Hearing Loss (Business Wire)
Nov-17-22 07:30AM	Frequency Therapeutics to Host Virtual Investor Event, Highlighting Hearing Restoration Candidate FX-322 in Advance of Q1 Clinical Results (Business Wire) -10.05%
Nov-08-22 04:05PM	Frequency Therapeutics Provides Business Updates and Third Quarter 2022 Financial Results (Business Wire) -9.51%
Oct-12-22 07:30AM	Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss (Business Wire) +7.47%
Aug-30-22 07:30AM	Frequency Therapeutics to Participate in September Investor and Medical Conferences (Business Wire)
Aug-09-22 04:05PM	Frequency Therapeutics Provides Business Updates and Second Quarter 2022 Financial Results (Business Wire) -11.11% +9.00%
Jun-24-22 09:03AM	Frequency Therapeutics (NASDAQ:FREQ) one-year losses have grown faster than shareholder returns have fallen, but the stock jumps 41% this past week (Simply Wall St.) -7.59%
May-25-22 12:00PM	Frequency Therapeutics, Inc. (FREQ) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
May-18-22 07:30AM	Frequency Therapeutics to Participate in 2022 H.C. Wainwright Global Investment Conference (Business Wire) -9.02%
May-04-22 04:30PM	Frequency Therapeutics Provides Business Updates and First Quarter 2022 Financial Results (Business Wire)
Apr-22-22 07:30AM	Frequency Therapeutics to Participate in B. Riley Securities Neuro & Ophthalmology Investor Conference (Business Wire)
Apr-08-22 05:00PM	Frequency Exchange Corp. Virtually Closes the Market (PR Newswire) -8.82%
Mar-15-22 07:30AM	Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2021 Financial Results (Business Wire) +15.29%
Mar-10-22 06:35PM	Poseida Therapeutics, Inc. (PSTX) Beats Q4 Earnings and Revenue Estimates (Zacks) -13.70%
Feb-28-22 07:30AM	Frequency Therapeutics to Participate in Upcoming March 2022 Investor Conferences (Business Wire)
Jan-14-22 05:43AM	One Frequency Therapeutics, Inc. (NASDAQ:FREQ) insider upped their stake in the previous year (Simply Wall St.)
Jan-04-22 07:30AM	Frequency Therapeutics to Present 2022 Business and Pipeline Overview at the 40th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-28-21 02:38AM	Destra Investment Trust Buys ThredUp Inc, Etsy Inc, Riskified, Sells , , 2U Inc (GuruFocus.com) +5.28%
Dec-09-21 01:18PM	Frequency Therapeutics' Hearing Loss Candidate Shows Improved Speech Perception In Noise (Benzinga)
07:30AM	Frequency Therapeutics Shares Results from FX-322-113 Severe Sensorineural Hearing Loss Study Showing Speech Perception Improvements in Noise (Business Wire)
Nov-30-21 05:53AM	Frequency Therapeutics (NASDAQ:FREQ) investors are sitting on a loss of 81% if they invested a year ago (Simply Wall St.)
Nov-15-21 12:25PM	Frequency Therapeutics, Inc. (FREQ) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:30AM	Frequency Therapeutics Provides Business Updates and Third Quarter 2021 Financial Results (Business Wire)
Nov-09-21 07:30AM	Frequency Therapeutics Holds Virtual R&D Event Highlighting Clinical Advancement of FX-322, a New Potential Restorative Treatment for Hearing Loss and In Vivo Data for Its Remyelination Program in Multiple Sclerosis (Business Wire)
Nov-08-21 03:00PM	Analysts Estimate Frequency Therapeutics, Inc. (FREQ) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-27-21 07:30AM	Frequency Therapeutics Virtual R&D Event to Detail FX-322 Clinical Advances, a New Program for Hearing Restoration and In Vivo Data from its MS Remyelination Program (Business Wire)
Oct-21-21 07:30AM	Frequency Therapeutics Announces First Subject Dosed in FX-322 Phase 2b Acquired Sensorineural Hearing Loss (SNHL) Study and FDA Agreement on Speech Perception as Primary Endpoint (Business Wire)
Oct-01-21 08:23AM	Do Insiders Own Lots Of Shares In Frequency Therapeutics, Inc. (NASDAQ:FREQ)? (Simply Wall St.)
Sep-22-21 11:18AM	Frequency Therapeutics' New Data Of Hearing Loss Candidate Fails To Impress Investors (Benzinga)
07:30AM	Frequency Therapeutics Announces New FX-322 Results Showing That Additional Study Participants Gain Hearing Improvements at Later Time Points (Business Wire)
Sep-08-21 07:30AM	Frequency Therapeutics to Present at Upcoming Investor Conferences (Business Wire)
Aug-30-21 05:10PM	Lifshitz Law Firm, P.C. Announces Investigations of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Frequency Therapeutics, Inc. (NasdaqGS: FREQ), RLX Technology Inc. (NYSE: RLX), and Washington Prime Group, Inc. (NYSE: WPG) (ACCESSWIRE)
Aug-12-21 04:06PM	Moore Kuehn, PLLC Encourages Investors of FREQ to Contact Law Firm (Newsfile)
08:45AM	Frequency Therapeutics, Inc. (FREQ) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Frequency Therapeutics Provides Business Updates and Second Quarter 2021 Financial Results (Business Wire)
Aug-04-21 03:00PM	Analysts Estimate Frequency Therapeutics, Inc. (FREQ) to Report a Decline in Earnings: What to Look Out for (Zacks)
Aug-02-21 03:05PM	CLASS ACTION UPDATE for JRVR, FREQ and QFIN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders (ACCESSWIRE)
02:30PM	Final Deadline Alert: Frequency Therapeutics, Inc. (FREQ) Class Action and Last Chance for Investors to Actively Participate - Bronstein, Gewirtz & Grossman, LLC (ACCESSWIRE)
12:30PM	SHAREHOLDER ALERT: FREQ RKT QFIN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines (ACCESSWIRE)
12:30PM	FINAL DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Frequency Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm (ACCESSWIRE)
11:00AM	FREQ Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Frequency Therapeutics, Inc. (FREQ) Shareholders of Class Action and Lead Plaintiff Deadline: August 2, 2021 (ACCESSWIRE)
10:00AM	The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of FREQ, RKT and BZ (ACCESSWIRE)
09:16AM	FREQ Final Deadline Today: Rosen, National Trial Lawyers, Encourages Frequency Therapeutics, Inc. Investors to Secure Counsel Before Important August 2 Deadline in Securities Class Action - FREQ (Newsfile)
09:09AM	DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Frequency Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm (Newsfile)
05:50AM	The Gross Law Firm Announces Class Actions on Behalf of Shareholders of FREQ, RLX and DIDI (ACCESSWIRE)
03:27AM	Frequency Therapeutics (NASDAQ:FREQ) Has Debt But No Earnings; Should You Worry? (Simply Wall St.)
Aug-01-21 10:38AM	FREQUENCY DEADLINE ALERT: Faruqi & Faruqi LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Frequency To Contact Him Directly To Discuss Their Options (GlobeNewswire)
06:36AM	FREQ FINAL DEADLINE: ROSEN, A TOP RANKED FIRM, Encourages Frequency Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline Tomorrow in Securities Class Action - FREQ (Newsfile)
Jul-30-21 08:49PM	DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Frequency Therapeutics, Inc. and Encourages Investors to Contact the Firm (Business Wire)
07:19PM	Frequency Therapeutics, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm (GlobeNewswire)
07:10PM	SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Frequency Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - FREQ (ACCESSWIRE)
05:15PM	FREQ Final Deadline Monday: Rosen, Leading Trial Attorneys, Encourages Frequency Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important August 2 Deadline in Securities Class Action - FREQ (Newsfile)
02:57PM	FREQ LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Frequency Therapeutics, Inc. (Newsfile)
01:30PM	FINAL DEADLINE IMMINENT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Frequency Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm (ACCESSWIRE)
12:40PM	The Gross Law Firm Announces Class Actions on Behalf of Shareholders of FREQ, OCGN and BLCT (ACCESSWIRE)
11:30AM	The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Frequency Therapeutics, Inc. (FREQ) (Business Wire)
11:30AM	CLASS ACTION UPDATE for CCIV, FREQ and RLX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders (ACCESSWIRE)
11:00AM	FREQ INVESTOR ALERT: Shareholder Lawsuit Deadline Approaching (ACCESSWIRE)
10:00AM	SHAREHOLDER ALERT: FREQ RLX DIDI: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines (ACCESSWIRE)
10:00AM	FREQ Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Frequency Therapeutics, Inc. (FREQ) Shareholders of Class Action and Lead Plaintiff Deadline: August 2, 2021 (GlobeNewswire)
09:30AM	MONDAY DEADLINE NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Frequency Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm (Newsfile)
09:00AM	FREQUENCY THERAPEUTICS SHAREHOLDERS: August 2, 2021 Filing Deadline in Class Action - Contact Lieff Cabraser (ACCESSWIRE)
05:18AM	FREQ ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of August 2, 2021 in the Class Action Filed on Behalf of Frequency Therapeutics, Inc. Limited Shareholders (Newsfile)
Jul-29-21 08:47PM	Frequency Class Action Reminder (Newsfile)
05:29PM	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Frequency Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 2, 2021 - FREQ (Newsfile)
04:02PM	MONDAY DEADLINE: Investors with Substantial Losses Have Opportunity to Lead the Frequency Therapeutics, Inc. Class Action Lawsuit - FREQ (PR Newswire)
01:15PM	The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of FREQ, RLX and OTLY (ACCESSWIRE)
12:30PM	FREQ DEADLINE ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Frequency Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Monday Deadline in Securities Class Action FREQ (GlobeNewswire)

Korro Bio, Inc. is an RNA editing company, which engages in the discovery and development of genetic medicines. The company was founded by Nessan Bermingham, Jean-Francois Formela, Joshua Rosenthal, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Colletti Steve	Former Officer	Aug 30 '24	Proposed Sale	49.24	10,303	507,326		Aug 30 05:28 PM
New Enterprise Associates 17,	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
BASKETT FOREST	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
Florence Anthony A. Jr.	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
Walker Paul Edward	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
Chang Carmen	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
Mathers Edward T	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
Yang Rick	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
Makhzoumi Mohamad	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
SANDELL SCOTT D	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
Atlas Venture Opportunity Fund	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	195,074	Apr 23 05:23 PM
Lucchino David L.	Director	Nov 22 '23	Sale	37.69	1,156	43,573	22,150	Nov 27 08:48 PM
Lucchino David L.	Director	Nov 10 '23	Sale	41.97	968	40,632	23,306	Nov 22 04:05 PM

Open in Screener

NET

Cloudflare Inc

Sep 06 • 04:00PM ET

76.05

Dollar change -2.35
Percentage change -3.00	%

Technology • Software - Infrastructure • USA • NYSE

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI VO VXF CIBR VUG VGT VOT IWP FDN IWF

Index	-	P/E	-	EPS (ttm)	-0.30	Insider Own	12.72%	Shs Outstand	341.70M	Perf Week	-6.43%
Market Cap	25.99B	Forward P/E	90.31	EPS next Y	0.84	Insider Trans	-4.87%	Shs Float	298.24M	Perf Month	-0.42%
Income	-102.02M	PEG	-	EPS next Q	0.18	Inst Own	83.65%	Short Float	3.26%	Perf Quarter	6.74%
Sales	1.48B	P/S	17.59	EPS this Y	44.96%	Inst Trans	-0.16%	Short Ratio	3.73	Perf Half Y	-24.52%
Book/sh	2.58	P/B	29.46	EPS next Y	18.55%	ROA	-3.74%	Short Interest	9.73M	Perf Year	18.85%
Cash/sh	5.15	P/C	14.78	EPS next 5Y	-	ROE	-13.39%	52W Range	53.88 - 116.00	Perf YTD	-8.66%
Dividend Est.	-	P/FCF	162.95	EPS past 5Y	-13.56%	ROI	-4.48%	52W High	-34.44%	Beta	1.11
Dividend TTM	-	Quick Ratio	3.51	Sales past 5Y	46.59%	Gross Margin	77.26%	52W Low	41.14%	ATR (14)	2.95
Dividend Ex-Date	-	Current Ratio	3.51	EPS Y/Y TTM	54.85%	Oper. Margin	-11.58%	RSI (14)	39.88	Volatility	4.00% 3.25%
Employees	3682	Debt/Eq	1.63	Sales Y/Y TTM	31.09%	Profit Margin	-6.90%	Recom	2.40	Target Price	91.34
Option/Short	Yes / Yes	LT Debt/Eq	1.59	EPS Q/Q	84.42%	Payout	-	Rel Volume	0.73	Prev Close	78.40
Sales Surprise	1.75%	EPS Surprise	42.05%	Sales Q/Q	29.99%	Earnings	Aug 01 AMC	Avg Volume	2.61M	Price	76.05
SMA20	-5.61%	SMA50	-5.45%	SMA200	-8.87%	Trades		Volume	1,900,875	Change	-3.00%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-16-24	Initiated	Wolfe Research	Peer Perform
Jul-08-24	Initiated	Scotiabank	Sector Perform	$85
Jun-25-24	Upgrade	UBS	Sell → Neutral	$76 → $82
May-07-24	Upgrade	DZ Bank	Hold → Buy	$95
Feb-13-24	Downgrade	DZ Bank	Buy → Hold	$110
Feb-09-24	Resumed	Cantor Fitzgerald	Neutral	$100
Jan-18-24	Initiated	Bernstein	Mkt Perform	$85
Jan-17-24	Initiated	CapitalOne	Equal Weight	$83
Dec-15-23	Initiated	Susquehanna	Neutral	$75
Nov-21-23	Upgrade	Oppenheimer	Perform → Outperform
Sep-07-23	Initiated	BofA Securities	Underperform	$52
Aug-07-23	Downgrade	Guggenheim	Neutral → Sell	$50
Jun-05-23	Initiated	UBS	Sell	$55
May-05-23	Upgrade	Guggenheim	Sell → Neutral
Apr-19-23	Resumed	William Blair	Outperform
Feb-14-23	Initiated	Goldman	Sell	$51
Feb-07-23	Initiated	Loop Capital	Hold	$52
Jan-17-23	Downgrade	Guggenheim	Neutral → Sell	$36
Nov-28-22	Resumed	JP Morgan	Neutral	$42
Nov-02-22	Initiated	Macquarie	Neutral	$60

Show Previous Ratings

Sep-05-24 02:52PM	US calls on Big Tech to help evade online censors in Russia, Iran (Reuters)
Sep-03-24 05:45AM	Should You Believe in the Long-Term Growth Prospects of Cloudflare (NET)? (Insider Monkey)
Aug-30-24 05:25AM	The Best Stocks to Invest $50,000 In Right Now (Motley Fool)
Aug-28-24 09:00AM	Is Trending Stock Cloudflare, Inc. (NET) a Buy Now? (Zacks)
05:12AM	2 Monster Growth Stocks to Buy Before Sales Soar 94% and 136%, According to Wall Street (Motley Fool)
09:05AM	Loading…
Aug-23-24 09:05AM	1 Cybersecurity Stock You Can Buy and Hold for the Next Decade (Motley Fool)
Aug-16-24 09:00AM	Cloudflare, Inc. (NET) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Aug-14-24 06:30AM	2 Stocks on My Market Sell-Off Watch List (Motley Fool)
Aug-13-24 12:50PM	Why Is Cloudflare (NET) Stock Soaring Today (StockStory) +6.68%
Aug-12-24 09:45AM	Here's Why Cloudflare (NET) is a Strong Growth Stock (Zacks)
Aug-07-24 03:16AM	Akamai (AKAM) Reports Q2: Everything You Need To Know Ahead Of Earnings (StockStory)
Aug-06-24 06:31AM	7 Cybersecurity Stocks That May Thrive in the Digital Age (InvestorPlace)
Aug-05-24 09:00AM	Cloudflare, Inc. (NET) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
Aug-03-24 01:04AM	Decoding Cloudflare Inc (NET): A Strategic SWOT Insight (GuruFocus.com)
Aug-02-24 03:42PM	Cloudflare stock jumps after raising full-year outlook (Yahoo Finance Video) +6.80%
11:54AM	Loading…
11:54AM	Why Cloudflare (NET) Stock Is Up Today (StockStory)
08:48AM	Analyst Report: Cloudflare, Inc. (Morningstar Research)
08:19AM	Cloudflare (NET) Soars 10% on Q2 Earnings Beat, Raised Guidance (Zacks)
07:20AM	Intel, Amazon, Nvidia, Snap fell premarket; Apple, Exxon rise (Investing.com)
12:45AM	Cloudflare (NET) Q2 2024 Earnings Call Transcript (Motley Fool)
Aug-01-24 06:00PM	Cloudflare (NET) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
05:38PM	Cloudflare Stock Climbs On Earnings, Revenue Beat, Guidance (Investor's Business Daily)
04:56PM	Cloudflare: Q2 Earnings Snapshot (Associated Press Finance)
04:43PM	Cloudflare raises full-year forecast after strong quarter, shares rise (Reuters)
04:28PM	Cloudflare (NYSE:NET) Exceeds Q2 Expectations, Stock Soars (StockStory)
04:15PM	Cloudflare Announces Second Quarter 2024 Financial Results (Business Wire)
Jul-31-24 03:05AM	Cloudflare (NET) Reports Q2: Everything You Need To Know Ahead Of Earnings (StockStory)
Jul-30-24 02:37PM	Cloudflare, Inc. (NET): The Best Cybersecurity Stock to Buy According to Hedge Funds? (Insider Monkey)
Jul-29-24 12:16PM	Akamai Stock Can Rise by 30%, Analyst Says. Heres How. (Barrons.com)
08:49AM	Should You Buy, Sell or Hold Cloudflare (NET) Ahead of Q2 Earnings? (Zacks)
05:50PM	Loading…
Jul-26-24 05:50PM	Cloudflare (NET) Increases Yet Falls Behind Market: What Investors Need to Know (Zacks)
Jul-22-24 06:00PM	Cloudflare (NET) Flat As Market Gains: What You Should Know (Zacks)
Jul-21-24 11:55PM	Cloudflare, Inc. (NET): Do Hedge Funds Think This Stock Will Skyrocket Soon? (Insider Monkey)
Jul-19-24 04:13PM	Heard on the Street: CrowdStrike May Get More Than a Slap (The Wall Street Journal)
Jul-17-24 09:27AM	Cloudflare (NET) Up 6% in a Month: How Should You Play Now? (Zacks)
Jul-16-24 06:00PM	Cloudflare (NET) Rises Yet Lags Behind Market: Some Facts Worth Knowing (Zacks)
Jul-15-24 10:00AM	7 Hypergrowth Stocks to Buy and Hold for 50 Years (InvestorPlace)
Jul-14-24 05:19AM	Better Tech Stock: Cloudflare vs. VeriSign (Motley Fool)
Jul-13-24 08:00AM	Stocks to Watch: 7 Under-the-Radar Companies Quietly Building Empires (InvestorPlace)
Jul-10-24 06:00PM	Cloudflare (NET) Stock Sinks As Market Gains: Here's Why (Zacks)
Jul-09-24 04:15PM	Cloudflare Announces Date of Second Quarter 2024 Financial Results (Business Wire)
03:22PM	3 Of the Best ETFs to Buy for AI Stocks Exposure (InvestorPlace)
10:15AM	Global Cybersecurity Market Size Expected to Reach $298 Billion By 2028 as Cyber Threats Skyrocket (GlobeNewswire)
06:42AM	7 Bullish Stock Picks With the Potential to Turn $5K Into $50K (InvestorPlace)
Jul-08-24 04:45PM	3 Smart Cybersecurity Stocks to Add to Your July Buy List (InvestorPlace)
Jul-03-24 05:11PM	Cloudflare launches a tool to combat AI bots (TechCrunch)
05:15AM	Software Development Stocks Q1 Results: Benchmarking F5 (NASDAQ:FFIV) (StockStory)
Jul-01-24 11:42AM	The 3 Best Cybersecurity Stocks to Buy in July 2024 (InvestorPlace)
Jun-30-24 01:00PM	The 3 Smartest AI Stocks to Buy With $5K Right Now (InvestorPlace)
Jun-28-24 05:50PM	Cloudflare (NET) Rises As Market Takes a Dip: Key Facts (Zacks)
12:15PM	Tech Companies Leading the Charge in the Transformative AI Era (PR Newswire)
07:33AM	Hot Stocks: 3 Untapped Opportunities for a 1,000% Return (InvestorPlace)
Jun-27-24 09:54AM	3 Cybersecurity Stocks That Could Make Your Grandchildren Rich (InvestorPlace)
09:45AM	Why Cloudflare (NET) is a Top Growth Stock for the Long-Term (Zacks)
Jun-25-24 09:00AM	New Cloudflare Report Shows Organizations Struggle with Outdated Security Approaches, While Online Threats Increase (Business Wire)
07:59AM	Software Development Stocks Q1 Teardown: JFrog (NASDAQ:FROG) Vs The Rest (StockStory)
Jun-24-24 06:00PM	Cloudflare (NET) Advances While Market Declines: Some Information for Investors (Zacks)
09:00AM	Cloudflare, Inc. (NET) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Jun-22-24 06:36AM	From $5k to $50k: 3 Stocks With Astronomical Upside Potential (InvestorPlace)
Jun-21-24 12:26PM	Key Tech Stocks Optimizing AI Usability and Infrastructure for a $20-Trillion Future (PR Newswire)
Jun-20-24 01:01PM	Earn Passive income Cloud Mining through DigitMiner (Insider Monkey)
Jun-18-24 06:00PM	Cloudflare (NET) Laps the Stock Market: Here's Why (Zacks)
04:00AM	European Businesses Anticipate More Cybersecurity Attacks, But Feel Unprepared for Them (Business Wire)
Jun-11-24 09:00AM	Cloudflare, Inc. (NET) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
Jun-08-24 12:44PM	The 7 Best Cybersecurity Stocks to Buy in June 2024 (InvestorPlace)
Jun-07-24 05:50PM	Cloudflare (NET) Dips More Than Broader Market: What You Should Know (Zacks)
Jun-06-24 06:19AM	7 Stocks That Could Safely 10X by 2030 (InvestorPlace)
06:00AM	Cloudflares Project Galileo Turns 10: Marks One Decade of Protecting At-Risk Organizations Online (Business Wire)
Jun-04-24 09:23AM	The 3 Most Undervalued Metaverse Stocks to Buy in June 2024 (InvestorPlace)
Jun-03-24 11:54AM	Passive Income Strategies for Crypto Investors - BluestoneMining (Insider Monkey)
May-31-24 11:04AM	Zscaler Stock Jumps on Unexpected Profit (Investopedia)
May-30-24 05:17PM	Salesforce, UiPath, and More Enterprise Software Stocks Swoon on Weak Results (Barrons.com) -9.60%
09:00AM	CrowdStrike and Cloudflare Announce Expanded Strategic Partnership to Secure Networks and Power the AI-Native SOC (Business Wire)
08:00AM	Cloudflare Acquires BastionZero to Add Zero Trust Infrastructure Access Controls for Cloudflare One, the Worlds Largest Secure Access Service Edge (SASE) Network (Business Wire)
May-29-24 09:00AM	Investors Heavily Search Cloudflare, Inc. (NET): Here is What You Need to Know (Zacks)
May-28-24 08:35AM	With Crypto Values Unstable Lately, How To Maintain Passive Income With BluestoneMining (Insider Monkey)
May-26-24 05:35AM	Time to Buy the Dip on Cloudflare Stock? (Motley Fool)
May-24-24 06:45AM	The 2034 Millionaire's Club: 3 Machine Learning Stocks to Buy Now (InvestorPlace)
May-16-24 06:45AM	7 Explosive Tech Stocks Set to Dominate the Decade (InvestorPlace)
May-15-24 08:00AM	Charge Up Your Stock Chart Analysis By Studying Volume In Bases (Investor's Business Daily)
May-14-24 09:00AM	Here is What to Know Beyond Why Cloudflare, Inc. (NET) is a Trending Stock (Zacks)
May-09-24 04:52PM	Cloudflare Insider Sold Shares Worth $2,196,419, According to a Recent SEC Filing (MT Newswires)
01:31PM	U.S. Department of Treasury, Pacific Northwest National Laboratory, and Cloudflare Partner to Share Early Warning Threat Intelligence for Financial Institutions (Business Wire)
05:30AM	1 Top Growth Stock Down 31% You May Regret Not Buying Right Now as It Could Soar 91% (Motley Fool)
May-08-24 06:16AM	Cloudflare Stock Has 48% Upside, According to 1 Wall Street Analyst (Motley Fool)
May-07-24 09:35AM	Here's Why Cloudflare (NET) is Poised for a Turnaround After Losing -22.06% in 4 Weeks (Zacks)
09:00AM	Cloudflare Announces Unified Risk Posture to Provide Comprehensive and Continuous Risk Management at Scalefor Free (Business Wire)
07:52AM	Macquarie Lowers Price Target on Cloudflare to $80 From $105, Keeps Neutral Rating (MT Newswires)
May-06-24 05:15PM	Where Will Cloudflare Stock Be in 1 Year? (Motley Fool)
04:39PM	Cloudflare Insider Sold Shares Worth $1,109,477, According to a Recent SEC Filing (MT Newswires)
09:00AM	Here is What to Know Beyond Why Cloudflare, Inc. (NET) is a Trending Stock (Zacks)
07:07AM	Is Cloudflare Stock Going to $94? 1 Wall Street Analyst Thinks So. (Motley Fool)
03:17AM	What To Expect From Bandwidth's (BAND) Q1 Earnings (StockStory)
May-03-24 05:41PM	Cloudflare Insider Sold Shares Worth $264,360, According to a Recent SEC Filing (MT Newswires) -16.38%
04:51PM	These Stocks Moved the Most Today: Apple, Amgen, Expedia, Coinbase, Cloudflare, Fortinet, Live Nation, and More (Barrons.com)
04:15PM	Cloudflare Tumbles As Revenue Outlook Underwhelms Investors (Investor's Business Daily)
03:46PM	Cloudflare stock plunges on lackluster Q2 revenue forecast (Yahoo Finance Video)
03:46PM	These Stocks Are Moving the Most Today: Apple, Amgen, Expedia, Coinbase, Cloudflare, Fortinet, Live Nation, and More (Barrons.com)
01:57PM	Cybersecurity Firm Fortinet's Billings Drag Stock Despite Revenue and Earnings Beat (Investopedia)
01:36PM	Stocks surge as soft jobs report revives Fed rate cut hopes: Yahoo Finance (Yahoo Finance Video)

Cloudflare, Inc. engages in the provision of cloud-based services to secure websites. It offers various products for performance and reliability, video streaming and delivery, advanced security, insights, Cloudflare for developers, domain registration and Cloudflare marketplace. It operates through United States and Rest of the World geographical segments. The company was founded by Matthew Prince, Michelle Zatlyn and Lee Holloway in July 2009 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Prince Matthew	CEO & Chair of the Board	Sep 05 '24	Sale	78.51	52,384	4,112,554	10,761	Sep 06 09:03 PM
Prince Matthew	CEO & Chair of the Board	Sep 04 '24	Sale	78.06	52,384	4,089,133	10,761	Sep 06 09:03 PM
Prince Matthew	CEO & Chair of the Board	Sep 06 '24	Sale	76.55	52,384	4,009,768	10,761	Sep 06 09:03 PM
SEIFERT THOMAS J	CHIEF FINANCIAL OFFICER	Sep 04 '24	Sale	78.05	15,000	1,170,818	281,403	Sep 05 04:35 PM
Kramer Douglas James	CHIEF LEGAL OFFICER	Sep 03 '24	Sale	81.53	3,000	244,590	185,386	Sep 04 04:26 PM
THOMAS J SEIFERT	Officer	Sep 04 '24	Proposed Sale	78.11	15,000	1,171,650		Sep 04 04:14 PM
DOUGLAS KRAMER	Officer	Sep 03 '24	Proposed Sale	81.53	3,000	244,590		Sep 03 04:15 PM
Zatlyn Michelle	President and COO	Aug 20 '24	Sale	83.74	35,117	2,940,717	0	Aug 22 07:23 PM
Zatlyn Michelle	President and COO	Aug 22 '24	Sale	81.91	25,640	2,100,243	0	Aug 22 07:23 PM
Zatlyn Michelle	President and COO	Aug 21 '24	Sale	81.74	25,640	2,095,826	0	Aug 22 07:23 PM
SEIFERT THOMAS J	CHIEF FINANCIAL OFFICER	Aug 20 '24	Sale	82.84	28,636	2,372,117	281,403	Aug 22 04:12 PM
Michelle Zatlyn	Officer	Aug 20 '24	Proposed Sale	82.38	240,237	19,790,724		Aug 20 04:46 PM
THOMAS J SEIFERT	Officer	Aug 20 '24	Proposed Sale	84.07	28,636	2,407,429		Aug 20 04:29 PM
Riley Janel	CHIEF ACCOUNTING OFFICER	May 29 '24	Sale	73.47	17,938	1,317,982	87,270	Aug 16 05:19 PM
Riley Janel	CHIEF ACCOUNTING OFFICER	Aug 16 '24	Sale	81.65	3,495	285,375	80,183	Aug 16 05:19 PM
Prince Matthew	CEO & Chair of the Board	Aug 07 '24	Sale	78.17	52,384	4,094,614	0	Aug 09 07:05 PM
Prince Matthew	CEO & Chair of the Board	Aug 09 '24	Sale	77.86	52,384	4,078,387	0	Aug 09 07:05 PM
Prince Matthew	CEO & Chair of the Board	Aug 08 '24	Sale	76.70	52,384	4,017,884	0	Aug 09 07:05 PM
Matthew Prince	Officer	Aug 07 '24	Proposed Sale	76.37	471,456	36,005,095		Aug 07 05:12 PM
SEIFERT THOMAS J	CHIEF FINANCIAL OFFICER	Aug 02 '24	Sale	78.71	15,000	1,180,714	309,937	Aug 05 05:30 PM
THOMAS J SEIFERT	Officer	Aug 02 '24	Proposed Sale	74.40	15,000	1,116,000		Aug 02 04:21 PM
Kramer Douglas James	CHIEF LEGAL OFFICER	Aug 01 '24	Sale	77.17	3,000	231,510	195,303	Aug 02 04:16 PM
Eitel Maria S	Director	Aug 01 '24	Sale	77.68	6,875	534,016	12,802	Aug 02 04:07 PM
DOUGLAS KRAMER	Officer	Aug 01 '24	Proposed Sale	77.17	3,000	231,510		Aug 01 04:25 PM
MARIA EITEL	Director	Aug 01 '24	Proposed Sale	77.68	6,875	534,016		Aug 01 04:16 PM
SEIFERT THOMAS J	CHIEF FINANCIAL OFFICER	Jul 18 '24	Sale	78.89	15,000	1,183,382	309,937	Jul 19 05:35 PM
Prince Matthew	CEO & Chair of the Board	Jul 09 '24	Sale	82.96	52,384	4,345,580	8,742	Jul 11 07:09 PM
Prince Matthew	CEO & Chair of the Board	Jul 11 '24	Sale	82.67	52,384	4,330,796	8,742	Jul 11 07:09 PM
Prince Matthew	CEO & Chair of the Board	Jul 10 '24	Sale	81.36	52,384	4,262,027	8,742	Jul 11 07:09 PM
Zatlyn Michelle	President and COO	Jul 01 '24	Sale	82.52	102,580	8,464,511	0	Jul 03 05:45 PM
Zatlyn Michelle	President and COO	Jul 03 '24	Sale	85.28	25,640	2,186,550	0	Jul 03 05:45 PM
Zatlyn Michelle	President and COO	Jul 02 '24	Sale	84.49	25,640	2,166,370	0	Jul 03 05:45 PM
SEIFERT THOMAS J	CHIEF FINANCIAL OFFICER	Jul 03 '24	Sale	84.97	15,000	1,274,571	309,937	Jul 03 04:57 PM
Kramer Douglas James	CHIEF LEGAL OFFICER	Jul 01 '24	Sale	82.65	3,000	247,950	195,303	Jul 02 04:28 PM
Ledbetter Carl	Director	Jun 26 '24	Sale	79.89	8,030	641,500	1,084,364	Jun 26 06:04 PM
SEIFERT THOMAS J	CHIEF FINANCIAL OFFICER	Jun 20 '24	Sale	78.47	15,000	1,176,991	309,937	Jun 24 04:18 PM
Zatlyn Michelle	President and COO	Jun 20 '24	Sale	78.51	12,820	1,006,444	0	Jun 21 07:10 PM
Zatlyn Michelle	President and COO	Jun 18 '24	Sale	77.54	12,820	994,120	0	Jun 21 07:10 PM
Zatlyn Michelle	President and COO	Jun 21 '24	Sale	76.41	12,820	979,573	0	Jun 21 07:10 PM
Ledbetter Carl	Director	Jun 20 '24	Sale	78.56	10,015	786,785	1,092,394	Jun 20 04:26 PM
Prince Matthew	CEO & Chair of the Board	Jun 12 '24	Sale	75.07	52,384	3,932,231	8,742	Jun 13 08:08 PM
Prince Matthew	CEO & Chair of the Board	Jun 13 '24	Sale	74.46	52,384	3,900,705	8,742	Jun 13 08:08 PM
Prince Matthew	CEO & Chair of the Board	Jun 11 '24	Sale	72.04	52,384	3,773,618	8,742	Jun 13 08:08 PM
Ledbetter Carl	Director	Jun 12 '24	Sale	74.48	7,986	594,781	1,102,409	Jun 13 04:13 PM
SEIFERT THOMAS J	CHIEF FINANCIAL OFFICER	Jun 05 '24	Sale	69.12	15,000	1,036,794	309,937	Jun 06 04:09 PM
Suder Katrin	Director	Jun 04 '24	Sale	67.11	574	38,521	51,162	Jun 05 05:15 PM
Ledbetter Carl	Director	Jun 05 '24	Sale	68.65	30,270	2,077,911	1,110,395	Jun 05 05:13 PM
Kramer Douglas James	CHIEF LEGAL OFFICER	Jun 03 '24	Sale	68.77	3,000	206,310	195,303	Jun 04 04:28 PM
Ledbetter Carl	Director	May 29 '24	Sale	72.79	7,994	581,848	1,140,665	May 29 04:13 PM
Ledbetter Carl	Director	May 22 '24	Sale	73.84	9,999	738,364	1,148,659	May 23 04:21 PM
Zatlyn Michelle	President and COO	May 20 '24	Sale	74.94	60,863	4,560,938	0	May 22 07:50 PM
Zatlyn Michelle	President and COO	May 21 '24	Sale	74.46	12,820	954,538	0	May 22 07:50 PM
Zatlyn Michelle	President and COO	May 22 '24	Sale	74.08	12,820	949,744	0	May 22 07:50 PM
SEIFERT THOMAS J	CHIEF FINANCIAL OFFICER	May 20 '24	Sale	75.13	28,634	2,151,359	309,937	May 21 04:59 PM
Ledbetter Carl	Director	May 15 '24	Sale	74.56	7,990	595,766	1,158,658	May 16 04:19 PM
Ledbetter Carl	Director	May 08 '24	Sale	72.86	30,145	2,196,419	1,166,648	May 09 04:29 PM
Prince Matthew	CEO & Chair of the Board	May 06 '24	Sale	74.67	52,384	3,911,545	0	May 08 06:54 PM
Prince Matthew	CEO & Chair of the Board	May 07 '24	Sale	74.14	52,384	3,883,938	0	May 08 06:54 PM
Prince Matthew	CEO & Chair of the Board	May 08 '24	Sale	72.51	52,384	3,798,564	0	May 08 06:54 PM
SEIFERT THOMAS J	CHIEF FINANCIAL OFFICER	May 03 '24	Sale	73.97	15,000	1,109,476	338,469	May 06 04:17 PM
Kramer Douglas James	CHIEF LEGAL OFFICER	May 01 '24	Sale	88.12	3,000	264,360	205,238	May 03 05:39 PM
Ledbetter Carl	Director	May 01 '24	Sale	87.49	8,022	701,860	1,196,793	May 02 04:51 PM
Eitel Maria S	Director	May 01 '24	Sale	88.12	6,875	605,825	16,638	May 02 04:48 PM
Ledbetter Carl	Director	Apr 24 '24	Sale	89.16	10,015	892,960	1,204,815	Apr 25 04:49 PM
SEIFERT THOMAS J	CHIEF FINANCIAL OFFICER	Apr 18 '24	Sale	87.02	15,000	1,305,249	338,469	Apr 19 05:18 PM
Zatlyn Michelle	President and COO	Apr 16 '24	Sale	89.69	25,640	2,299,578	19,615	Apr 18 08:14 PM
Zatlyn Michelle	President and COO	Apr 17 '24	Sale	90.10	19,505	1,757,371	19,615	Apr 18 08:14 PM
Zatlyn Michelle	President and COO	Apr 18 '24	Sale	87.07	18,955	1,650,463	19,615	Apr 18 08:14 PM
Ledbetter Carl	Director	Apr 17 '24	Sale	90.39	8,029	725,769	1,214,830	Apr 18 06:46 PM
Prince Matthew	CEO & Chair of the Board	Apr 09 '24	Sale	96.04	52,384	5,030,854	0	Apr 11 08:22 PM
Prince Matthew	CEO & Chair of the Board	Apr 11 '24	Sale	95.29	52,384	4,991,826	0	Apr 11 08:22 PM
Prince Matthew	CEO & Chair of the Board	Apr 10 '24	Sale	94.94	52,384	4,973,089	0	Apr 11 08:22 PM
Ledbetter Carl	Director	Apr 10 '24	Sale	94.37	44,154	4,166,635	1,222,859	Apr 11 06:42 PM
Ledbetter Carl	Director	Apr 03 '24	Sale	94.05	7,991	751,566	1,267,013	Apr 04 03:35 PM
SEIFERT THOMAS J	CHIEF FINANCIAL OFFICER	Apr 03 '24	Sale	94.91	15,000	1,423,642	338,469	Apr 04 03:31 PM
Kramer Douglas James	CHIEF LEGAL OFFICER	Apr 01 '24	Sale	97.16	3,000	291,480	205,238	Apr 02 04:59 PM
Ledbetter Carl	Director	Mar 27 '24	Sale	100.16	9,993	1,000,916	1,275,004	Mar 28 04:06 PM
Ledbetter Carl	Director	Mar 20 '24	Sale	95.08	7,968	757,605	1,284,997	Mar 20 06:59 PM
SEIFERT THOMAS J	Chief Financial Officer	Mar 15 '24	Sale	91.77	95,000	8,718,453	0	Mar 19 04:10 PM
SEIFERT THOMAS J	Chief Financial Officer	Mar 15 '24	Sale	91.77	15,000	1,376,562	338,469	Mar 19 04:10 PM
Prince Matthew	CEO & Chair of the Board	Mar 13 '24	Sale	96.83	52,384	5,072,501	12,183	Mar 14 08:11 PM
Prince Matthew	CEO & Chair of the Board	Mar 12 '24	Sale	96.66	52,384	5,063,274	12,183	Mar 14 08:11 PM
Prince Matthew	CEO & Chair of the Board	Mar 14 '24	Sale	94.25	52,384	4,937,165	12,183	Mar 14 08:11 PM
Ledbetter Carl	Director	Mar 13 '24	Sale	96.43	44,099	4,252,598	1,292,965	Mar 14 04:29 PM
Zatlyn Michelle	President and COO	Mar 08 '24	Sale	101.02	25,640	2,590,144	19,615	Mar 08 07:20 PM
Zatlyn Michelle	President and COO	Mar 07 '24	Sale	98.72	25,640	2,531,290	19,615	Mar 08 07:20 PM
Zatlyn Michelle	President and COO	Mar 06 '24	Sale	97.96	25,640	2,511,730	19,615	Mar 08 07:20 PM
Ledbetter Carl	Director	Mar 06 '24	Sale	98.35	8,022	788,947	1,337,064	Mar 07 06:14 PM
Kramer Douglas James	CHIEF LEGAL OFFICER	Mar 04 '24	Sale	99.64	3,000	298,920	205,238	Mar 05 06:15 PM
SEIFERT THOMAS J	CHIEF FINANCIAL OFFICER	Mar 04 '24	Sale	99.87	15,000	1,498,088	338,469	Mar 05 06:12 PM
Eitel Maria S	Director	Feb 29 '24	Sale	98.51	6,875	677,248	23,513	Feb 29 05:56 PM
Ledbetter Carl	Director	Feb 28 '24	Sale	96.35	10,010	964,484	1,345,086	Feb 29 05:19 PM
Prince Matthew	CEO & Chair of the Board	Feb 22 '24	Sale	99.17	52,384	5,194,859	12,183	Feb 23 08:19 PM
Prince Matthew	CEO & Chair of the Board	Feb 23 '24	Sale	98.75	52,384	5,173,032	12,183	Feb 23 08:19 PM
Prince Matthew	CEO & Chair of the Board	Feb 21 '24	Sale	94.59	52,384	4,955,066	12,183	Feb 23 08:19 PM
SEIFERT THOMAS J	CHIEF FINANCIAL OFFICER	Feb 20 '24	Sale	96.56	27,901	2,694,074	338,469	Feb 21 07:52 PM
Ledbetter Carl	Director	Feb 21 '24	Sale	94.74	7,970	755,054	1,355,096	Feb 21 04:32 PM
Zatlyn Michelle	President and COO	Feb 15 '24	Sale	101.17	277,376	28,063,427	38,545	Feb 20 08:08 PM
Zatlyn Michelle	President and COO	Feb 16 '24	Sale	99.32	158,524	15,744,242	0	Feb 20 08:08 PM
Zatlyn Michelle	President and COO	Feb 20 '24	Sale	96.32	25,640	2,469,563	0	Feb 20 08:08 PM

Open in Screener

SVRA

Savara Inc

Sep 06 • 04:00PM ET

4.42

Dollar change -0.12
Percentage change -2.64	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI IWM VXF XBI IWO IBB VTWO VHT IWC IWN

Index	RUT	P/E	-	EPS (ttm)	-0.42	Insider Own	44.35%	Shs Outstand	138.14M	Perf Week	4.74%
Market Cap	727.53M	Forward P/E	-	EPS next Y	-0.43	Insider Trans	0.00%	Shs Float	91.60M	Perf Month	10.50%
Income	-75.29M	PEG	-	EPS next Q	-0.11	Inst Own	51.06%	Short Float	9.58%	Perf Quarter	9.95%
Sales	0.00M	P/S	-	EPS this Y	-35.06%	Inst Trans	2.44%	Short Ratio	4.98	Perf Half Y	-20.93%
Book/sh	0.74	P/B	6.00	EPS next Y	3.85%	ROA	-58.02%	Short Interest	8.77M	Perf Year	16.93%
Cash/sh	0.74	P/C	5.99	EPS next 5Y	-	ROE	-79.48%	52W Range	3.12 - 5.70	Perf YTD	-5.96%
Dividend Est.	-	P/FCF	-	EPS past 5Y	29.09%	ROI	-58.72%	52W High	-22.46%	Beta	0.95
Dividend TTM	-	Quick Ratio	11.29	Sales past 5Y	-20.00%	Gross Margin	-	52W Low	41.89%	ATR (14)	0.24
Dividend Ex-Date	-	Current Ratio	11.29	EPS Y/Y TTM	-51.68%	Oper. Margin	0.00%	RSI (14)	52.72	Volatility	5.42% 5.10%
Employees	37	Debt/Eq	0.26	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	10.79
Option/Short	Yes / Yes	LT Debt/Eq	0.26	EPS Q/Q	-62.62%	Payout	-	Rel Volume	0.59	Prev Close	4.54
Sales Surprise	-	EPS Surprise	-15.05%	Sales Q/Q	-	Earnings	Aug 12 AMC	Avg Volume	1.76M	Price	4.42
SMA20	2.66%	SMA50	0.32%	SMA200	-2.34%	Trades		Volume	1,039,399	Change	-2.64%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-15-24	Initiated	JMP Securities	Mkt Outperform	$8
Nov-07-23	Initiated	Guggenheim	Buy	$7
May-16-23	Upgrade	Jefferies	Hold → Buy	$2 → $4
Mar-31-23	Downgrade	Jefferies	Buy → Hold	$2
Mar-16-21	Initiated	Piper Sandler	Overweight	$7
Mar-15-21	Initiated	Oppenheimer	Outperform	$4
Jun-13-19	Reiterated	H.C. Wainwright	Buy	$22 → $6
Jun-13-19	Downgrade	Ladenburg Thalmann	Buy → Neutral	$21 → $3
Jun-13-19	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Aug-13-18	Resumed	ROTH Capital	Neutral	$12
Jan-03-18	Initiated	Ladenburg Thalmann	Buy	$35
Sep-27-17	Resumed	ROTH Capital	Buy	$40
Sep-22-17	Initiated	Jefferies	Buy	$20
Sep-11-17	Initiated	JMP Securities	Mkt Outperform	$20

Show Previous Ratings

Sep-06-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Sep-03-24 04:05PM	Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Sep-01-24 10:26PM	Savara, Inc. (SVRA): The Best Multibagger Penny Stock of 2025? (Insider Monkey)
Aug-29-24 08:41PM	10 Best Multibagger Penny Stocks of 2025 (Insider Monkey)
Aug-16-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
08:05AM	Loading…
Aug-15-24 08:05AM	Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024 (Business Wire) +5.87%
Aug-12-24 04:05PM	Savara Reports Second Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Jun-29-24 08:35PM	Did Savara Inc. (SVRA) Receive a Good Rating from Wall Street Analysts in Q1? (Insider Monkey)
06:30PM	10 Best Biotech Penny Stocks to Buy Now (Insider Monkey)
Jun-28-24 08:50AM	Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock (Business Wire) +5.77%
Jun-26-24 07:41AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
06:30AM	Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Jun-25-24 08:05PM	Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Jun-19-24 09:00AM	3 Penny Stocks Poised for Major Upside Over the Next 5 Years (InvestorPlace)
Jun-11-24 06:00AM	3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition (InvestorPlace)
08:05AM	Loading…
May-29-24 08:05AM	Savara to Present at the Jefferies Global Healthcare Conference (Business Wire)
May-21-24 08:20AM	Oppenheimer Adjusts Savara Price Target to $11 From $9.50, Maintains Outperform Rating (MT Newswires)
May-19-24 12:15PM	Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024 (Business Wire)
May-16-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire) -5.08%
May-09-24 10:55PM	SVRA Stock Earnings: Savara Misses EPS for Q1 2024 (InvestorPlace) -8.19%
04:05PM	Savara Reports First Quarter 2024 Financial Results and Provides Business Update (Business Wire)
May-07-24 04:05PM	Savara to Present at the Citizens JMP Life Sciences Conference (Business Wire) +6.26% -5.13%
Apr-08-24 08:05AM	Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024 (Business Wire)
Mar-22-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Mar-07-24 10:54PM	SVRA Stock Earnings: Savara Beats EPS for Q4 2023 (InvestorPlace) -5.19%
04:05PM	Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update (Business Wire)
Mar-06-24 04:05PM	Savara to Present at the Barclays 26th Annual Global Healthcare Conference (Business Wire)
Feb-02-24 08:05AM	Savara Announces New Employment Inducement Grant (Business Wire)
Jan-31-24 08:05AM	Savara to Present at Two Upcoming Healthcare Conferences (Business Wire)
Dec-30-23 03:01PM	Insider Sell: CEO Matthew Pauls Disposes of 84,000 Shares of Savara Inc (SVRA) (GuruFocus.com)
08:05AM	Loading…
Dec-21-23 08:05AM	Savara Introduces aPAP ClearPath, a GM-CSF Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Dec-20-23 08:05AM	Savara Added to the NASDAQ Biotechnology Index (Business Wire)
Dec-15-23 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Nov-21-23 08:05AM	Savara to Present at the Piper Sandler 35th Annual Healthcare Conference (Business Wire)
Nov-09-23 04:05PM	Savara Reports Third Quarter Financial Results and Provides Business Update (Business Wire) -7.84%
Nov-08-23 04:05PM	Savara to Present at the Jefferies London Healthcare Conference (Business Wire)
Oct-06-23 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Sep-27-23 07:29PM	3 Penny Stocks to Provide 1,000% Returns Over the Next Decade (InvestorPlace)
Sep-17-23 10:54AM	15 Penny Stocks with Biggest Upside (Insider Monkey)
Sep-12-23 09:12AM	The 3 Best Penny Stocks to Buy Now: September 2023 (InvestorPlace)
Sep-05-23 04:05PM	Savara to Present at the H.C. Wainwright 25th Annual Global Investment Conference (Business Wire)
Aug-10-23 04:05PM	Savara Reports Second Quarter Financial Results and Provides Business Update (Business Wire)
Aug-04-23 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Jul-13-23 07:00AM	Savara Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (Business Wire) +8.92%
Jun-26-23 04:05PM	Savara Added to Russell 3000® Index (Business Wire) -7.34%
08:05AM	Savara Completes Enrollment of Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Jun-02-23 08:05AM	Savara to Present at the Jefferies Healthcare Conference (Business Wire)
May-28-23 08:26AM	Independent Director of Savara David Ramsay Buys 4.8% More Shares \ (Simply Wall St.)
May-16-23 12:32PM	Why Shares of Savara Jumped on Tuesday (Motley Fool) +9.09%
May-15-23 08:05AM	Savara Reports First Quarter Financial Results and Provides Business Update (Business Wire)
May-05-23 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire) +6.84%
Apr-03-23 07:33AM	Savara Inc. (NASDAQ:SVRA) Is Expected To Breakeven In The Near Future (Simply Wall St.) -6.15%
Mar-31-23 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Mar-30-23 04:05PM	Savara Reports Fourth Quarter / Year-End 2022 Financial Results and Provides Business Update (Business Wire)
Mar-20-23 06:35AM	Daily Vickers Top Insider Picks for 03/20/2023 (Argus Research)
Mar-17-23 06:47AM	Daily Vickers Top Insider Picks for 03/17/2023 (Argus Research) -7.31%
Mar-16-23 06:51AM	Daily Vickers Top Insider Picks for 03/16/2023 (Argus Research)
Mar-15-23 06:44AM	Daily Vickers Top Insider Picks for 03/15/2023 (Argus Research)
Mar-13-23 06:32AM	Daily Vickers Top Insider Picks for 03/13/2023 (Argus Research)
Mar-10-23 07:04AM	Daily Vickers Top Insider Picks for 03/10/2023 (Argus Research) -15.94%
Mar-09-23 06:33AM	Daily Vickers Top Insider Picks for 03/09/2023 (Argus Research)
Mar-08-23 06:30AM	Daily Vickers Top Insider Picks for 03/08/2023 (Argus Research)
Mar-07-23 06:34AM	Daily Vickers Top Insider Picks for 03/07/2023 (Argus Research)
Mar-06-23 04:05PM	Savara to Present at the Oppenheimer 33rd Annual Healthcare Conference (Business Wire)
07:22AM	Daily Vickers Top Insider Picks for 03/06/2023 (Argus Research)
Mar-03-23 06:38AM	Daily Vickers Top Insider Picks for 03/03/2023 (Argus Research) -7.42%
Mar-02-23 06:44AM	Daily Vickers Top Insider Picks for 03/02/2023 (Argus Research)
Mar-01-23 06:01AM	Daily Vickers Top Insider Picks for 03/01/2023 (Argus Research)
Feb-28-23 04:05PM	Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
06:43AM	Daily Vickers Top Insider Picks for 02/28/2023 (Argus Research)
Feb-27-23 06:50AM	Daily Vickers Top Insider Picks for 02/27/2023 (Argus Research)
Feb-23-23 07:21AM	Daily Vickers Top Insider Picks for 02/23/2023 (Argus Research)
Feb-22-23 06:56AM	Daily Vickers Top Insider Picks for 02/22/2023 (Argus Research)
Feb-21-23 07:35AM	Daily Vickers Top Insider Picks for 02/21/2023 (Argus Research)
Feb-17-23 06:27AM	Daily Vickers Top Insider Picks for 02/17/2023 (Argus Research)
Feb-16-23 07:28AM	Daily Vickers Top Insider Picks for 02/16/2023 (Argus Research)
Feb-15-23 07:01AM	Daily Vickers Top Insider Picks for 02/15/2023 (Argus Research) +6.52%
06:24AM	Savara Inc. (NASDAQ:SVRA) insiders placed bullish bets worth US$858k in the last 12 months (Simply Wall St.)
Feb-14-23 08:05AM	Savara Announces New Leadership Appointments (Business Wire)
06:23AM	Daily Vickers Top Insider Picks for 02/14/2023 (Argus Research)
Feb-13-23 07:30AM	Daily Vickers Top Insider Picks for 02/13/2023 (Argus Research)
Feb-10-23 06:42AM	Daily Vickers Top Insider Picks for 02/10/2023 (Argus Research)
Feb-09-23 06:51AM	Daily Vickers Top Insider Picks for 02/09/2023 (Argus Research)
Feb-08-23 06:45AM	Daily Vickers Top Insider Picks for 02/08/2023 (Argus Research) -5.16%
Feb-07-23 06:46AM	Daily Vickers Top Insider Picks for 02/07/2023 (Argus Research)
Feb-06-23 06:56AM	Daily Vickers Top Insider Picks for 02/06/2023 (Argus Research)
Feb-03-23 06:32AM	Daily Vickers Top Insider Picks for 02/03/2023 (Argus Research)
Feb-02-23 06:43AM	Daily Vickers Top Insider Picks for 02/02/2023 (Argus Research) -5.20%
Feb-01-23 06:14AM	Daily Vickers Top Insider Picks for 02/01/2023 (Argus Research)
Jan-31-23 06:50AM	Daily Vickers Top Insider Picks for 01/31/2023 (Argus Research)
Jan-30-23 06:42AM	Daily Vickers Top Insider Picks for 01/30/2023 (Argus Research)
Jan-27-23 03:47PM	Why Shares of Savara Soared This Week (Motley Fool)
07:00AM	Daily Vickers Top Insider Picks for 01/27/2023 (Argus Research)
Jan-26-23 06:44AM	Daily Vickers Top Insider Picks for 01/26/2023 (Argus Research)
Jan-25-23 06:39AM	Daily Vickers Top Insider Picks for 01/25/2023 (Argus Research) +8.02%
Jan-24-23 06:48AM	Daily Vickers Top Insider Picks for 01/24/2023 (Argus Research) +8.72%
Jan-23-23 06:58AM	Daily Vickers Top Insider Picks for 01/23/2023 (Argus Research)
Jan-20-23 08:05AM	Savara Announces New Employment Inducement Grant (Business Wire)
06:55AM	Daily Vickers Top Insider Picks for 01/20/2023 (Argus Research)
Jan-19-23 06:43AM	Daily Vickers Top Insider Picks for 01/19/2023 (Argus Research)

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Langhorne, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Pauls Matthew	CHIEF EXECUTIVE OFFICER	Dec 28 '23	Sale	4.71	84,000	395,900	1,302,674	Dec 29 04:35 PM
Lowrance David L	CHIEF FINANCIAL OFFICER	Dec 28 '23	Sale	4.71	10,000	47,131	342,355	Dec 29 04:34 PM
Elam Nevan C	Director	Dec 28 '23	Option Exercise	1.30	53,758	69,722	116,343	Dec 29 04:33 PM
Elam Nevan C	Director	Dec 28 '23	Sale	4.71	93,843	442,291	22,500	Dec 29 04:33 PM
Hawkins Richard J	Director	Dec 11 '23	Option Exercise	0.82	10,841	8,890	12,741	Dec 12 06:09 PM
Elam Nevan C	Director	Dec 11 '23	Option Exercise	0.82	10,841	8,890	40,085	Dec 12 06:08 PM

Open in Screener

GLYC

GlycoMimetics Inc

Sep 06 • 04:00PM ET

0.1571

Dollar change -0.0075
Percentage change -4.56	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

GLYC GlycoMimetics Inc daily Stock Chart

Held by: VTI VXF IWC

Index	-	P/E	-	EPS (ttm)	-0.61	Insider Own	8.38%	Shs Outstand	64.39M	Perf Week	-9.30%
Market Cap	10.13M	Forward P/E	-	EPS next Y	-0.43	Insider Trans	-26.51%	Shs Float	59.08M	Perf Month	-9.92%
Income	-39.11M	PEG	-	EPS next Q	-0.16	Inst Own	35.46%	Short Float	3.91%	Perf Quarter	-39.65%
Sales	0.01M	P/S	1012.98	EPS this Y	-4.74%	Inst Trans	-1.73%	Short Ratio	0.61	Perf Half Y	-94.39%
Book/sh	0.31	P/B	0.50	EPS next Y	28.40%	ROA	-90.71%	Short Interest	2.31M	Perf Year	-89.60%
Cash/sh	0.35	P/C	0.45	EPS next 5Y	-	ROE	-104.49%	52W Range	0.16 - 3.53	Perf YTD	-93.34%
Dividend Est.	-	P/FCF	-	EPS past 5Y	13.11%	ROI	-194.96%	52W High	-95.55%	Beta	2.05
Dividend TTM	-	Quick Ratio	5.48	Sales past 5Y	-53.76%	Gross Margin	-3102.77%	52W Low	-0.44%	ATR (14)	0.02
Dividend Ex-Date	-	Current Ratio	5.48	EPS Y/Y TTM	7.48%	Oper. Margin	-408772.17%	RSI (14)	32.43	Volatility	6.74% 8.89%
Employees	35	Debt/Eq	0.02	Sales Y/Y TTM	-86.67%	Profit Margin	-391135.91%	Recom	2.50	Target Price	0.75
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-21.87%	Payout	-	Rel Volume	0.11	Prev Close	0.16
Sales Surprise	-	EPS Surprise	-1.49%	Sales Q/Q	-	Earnings	Aug 01	Avg Volume	3.78M	Price	0.16
SMA20	-11.61%	SMA50	-31.82%	SMA200	-89.92%	Trades		Volume	402,726	Change	-4.56%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-26-24	Downgrade	TD Cowen	Buy → Hold
Dec-22-23	Initiated	CapitalOne	Overweight	$12
Nov-12-21	Upgrade	Jefferies	Hold → Buy	$3 → $4
Nov-14-19	Initiated	ROTH Capital	Buy	$12
Aug-05-19	Downgrade	SunTrust	Buy → Hold	$23 → $5
Aug-05-19	Downgrade	Piper Jaffray	Overweight → Neutral	$20 → $6
Aug-05-19	Downgrade	Jefferies	Buy → Hold
Apr-12-19	Initiated	Piper Jaffray	Overweight	$20
Dec-18-18	Initiated	H.C. Wainwright	Buy	$24
Jul-26-16	Initiated	SunTrust	Buy
Mar-17-15	Reiterated	Stifel	Buy	$13 → $14

Show Previous Ratings

Jul-25-24 09:00AM	GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan (Business Wire) -24.20%
Jul-22-24 07:00AM	7 Sorry Biotech Stocks Set to Make Investors Sad (InvestorPlace) +13.89%
Jun-26-24 07:41AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace) -12.60%
Jun-25-24 07:37AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace) +25.28%
Jun-04-24 07:00AM	GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) (Business Wire) +7.38%
04:01PM	Loading…
May-29-24 04:01PM	GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024 (Business Wire) +6.82%
May-28-24 04:05AM	Pipeline Moves: Phase III AML trial fails to meet primary endpoint (Clinical Trials Arena)
May-09-24 10:58PM	GLYC Stock Earnings: GlycoMimetics Misses EPS for Q1 2024 (InvestorPlace) -10.54%
07:19PM	GlycoMimetics: Q1 Earnings Snapshot (Associated Press Finance)
May-08-24 07:42AM	Uproleselans failed Phase III AML trial shakes up GlycoMimetics future (Clinical Trials Arena)
May-07-24 05:21AM	GlycoMimetics reports data from Phase III AML treatment trial (Clinical Trials Arena)
May-06-24 03:53PM	Sector Update: Health Care Stocks Higher in Late Afternoon Trading (MT Newswires) -82.76%
12:45PM	GlycoMimetics Shares Slump After Cancer Treatment Drug Combination Fails to Meet Primary Endpoint (MT Newswires)
08:40AM	Why Is GlycoMimetics (GLYC) Stock Down 77% Today? (InvestorPlace)
07:52AM	GlycoMimetics fails phase 3 blood cancer trial, causing investors to sour on stock (FierceBiotech.com)
07:28AM	Loading…
07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
06:00AM	GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) (Business Wire)
Apr-25-24 07:00AM	GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024 (Business Wire) -7.82%
Mar-28-24 10:12AM	GlycoMimetics, Inc. (NASDAQ:GLYC) Q4 2023 Earnings Call Transcript (Insider Monkey) -5.66%
02:10AM	Q4 2023 GlycoMimetics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-27-24 11:53AM	GLYC Stock Earnings: GlycoMimetics Beats EPS for Q4 2023 (InvestorPlace) +11.58%
10:31AM	GlycoMimetics Inc (GLYC) Posts Quarterly Loss, Aligns with Analyst Projections (GuruFocus.com)
07:14AM	GlycoMimetics: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023 (Business Wire)
Mar-21-24 08:50AM	Should You Buy GlycoMimetics (GLYC) Ahead of Earnings? (Zacks) -5.57%
Mar-13-24 07:00AM	GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024 (Business Wire)
Feb-26-24 07:00AM	GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference (Business Wire) +5.52%
Feb-12-24 07:00AM	GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire) -5.47%
Jan-04-24 07:00AM	GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687 (Business Wire)
Jan-03-24 07:00AM	Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia (GlobeNewswire) +11.40%
12:00PM	Loading…
Dec-10-23 12:00PM	GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia (Business Wire)
Nov-09-23 07:00AM	GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference (Business Wire) -10.45%
Nov-05-23 08:51AM	GlycoMimetics, Inc. (NASDAQ:GLYC) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-04-23 01:48AM	Q3 2023 GlycoMimetics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-03-23 10:33AM	GlycoMimetics Inc (GLYC) Reports Q3 2023 Financial Results (GuruFocus.com)
07:07AM	GlycoMimetics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023 (Business Wire)
Oct-23-23 08:30AM	Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory Board (PR Newswire) -7.14%
Oct-20-23 07:00AM	GlycoMimetics to Report Third Quarter 2023 Financial Results on November 3, 2023 (Business Wire)
Sep-06-23 07:00AM	GlycoMimetics Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687 (Business Wire)
Sep-05-23 07:00AM	GlycoMimetics to Participate in Upcoming H.C. Wainwright 25th Annual Global Investment Conference (Business Wire) -5.10%
Aug-17-23 07:00AM	GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-02-23 07:17AM	GlycoMimetics: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023 (Business Wire)
Jul-19-23 07:00AM	GlycoMimetics to Report Second Quarter 2023 Financial Results on August 2, 2023 (Business Wire) -6.43%
Jul-13-23 09:29AM	12 Best Multibagger Penny Stocks To Buy (Insider Monkey)
Jun-26-23 08:00AM	GlycoMimetics Announces Its Addition to the Russell Microcap® Index (Business Wire)
Jun-15-23 08:00AM	GlycoMimetics Announces U.S. Food and Drug Administration Clears Addition of Time-based Final Analysis to Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia (Business Wire) +8.52%
Jun-12-23 11:13AM	We Think GlycoMimetics (NASDAQ:GLYC) Needs To Drive Business Growth Carefully (Simply Wall St.)
May-31-23 07:00AM	GlycoMimetics to Participate in Upcoming Jefferies 2023 Healthcare Conference (Business Wire)
May-16-23 10:37AM	retail investors who own 36% along with institutions invested in GlycoMimetics, Inc. (NASDAQ:GLYC) saw increase in their holdings value last week (Simply Wall St.) -6.73%
May-03-23 10:17PM	Q1 2023 GlycoMimetics Inc Earnings Call (Thomson Reuters StreetEvents) +7.35%
07:23AM	GlycoMimetics: Q1 Earnings Snapshot (AP Finance)
07:00AM	GlycoMimetics Reports Highlights and Financial Results for First Quarter 2023 (Business Wire)
Apr-26-23 07:00AM	GlycoMimetics to Report First Quarter 2023 Financial Results on May 3, 2023 (Business Wire)
Apr-19-23 10:20AM	Possible turnaround for GlycoMimetics, Inc. (NASDAQ:GLYC) insiders, still down US$63k after a US$732k shopping spree (Simply Wall St.)
Apr-05-23 01:45PM	The Quant Trading System Picking Stocks That Soar 300% (InvestorPlace)
Mar-31-23 04:30AM	GlycoMimetics, Inc. (NASDAQ:GLYC) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-29-23 07:00AM	GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Year-end 2022 (Business Wire) -9.29%
Mar-21-23 06:23AM	Daily Vickers Top Insider Picks for 03/21/2023 (Argus Research)
Mar-20-23 06:35AM	Daily Vickers Top Insider Picks for 03/20/2023 (Argus Research)
Mar-17-23 06:47AM	Daily Vickers Top Insider Picks for 03/17/2023 (Argus Research) -5.41%
Mar-16-23 07:00AM	GlycoMimetics to Report Fourth Quarter and 2022 Full Year Financial Results on March 29, 2023 (Business Wire)
06:51AM	Daily Vickers Top Insider Picks for 03/16/2023 (Argus Research)
Mar-15-23 06:44AM	Daily Vickers Top Insider Picks for 03/15/2023 (Argus Research)
Mar-13-23 06:32AM	Daily Vickers Top Insider Picks for 03/13/2023 (Argus Research) +10.69%
Mar-10-23 07:04AM	Daily Vickers Top Insider Picks for 03/10/2023 (Argus Research)
Mar-09-23 06:33AM	Daily Vickers Top Insider Picks for 03/09/2023 (Argus Research) -9.52%
Mar-08-23 06:30AM	Daily Vickers Top Insider Picks for 03/08/2023 (Argus Research)
Mar-07-23 06:34AM	Daily Vickers Top Insider Picks for 03/07/2023 (Argus Research)
Mar-06-23 07:22AM	Daily Vickers Top Insider Picks for 03/06/2023 (Argus Research) -5.13%
Mar-03-23 06:38AM	Daily Vickers Top Insider Picks for 03/03/2023 (Argus Research)
Mar-02-23 06:44AM	Daily Vickers Top Insider Picks for 03/02/2023 (Argus Research)
Mar-01-23 07:00AM	GlycoMimetics to Participate in Upcoming Cowen 43rd Annual Health Care Conference (Business Wire)
06:01AM	Daily Vickers Top Insider Picks for 03/01/2023 (Argus Research)
06:01AM	Daily Vickers Top Buyers & Sellers for 03/01/2023 (Argus Research)
Feb-28-23 06:43AM	Daily Vickers Top Insider Picks for 02/28/2023 (Argus Research)
Feb-27-23 06:50AM	Daily Vickers Top Insider Picks for 02/27/2023 (Argus Research)
Feb-24-23 07:17AM	Daily Vickers Top Insider Picks for 02/24/2023 (Argus Research)
07:17AM	Daily Vickers Top Buyers & Sellers for 02/24/2023 (Argus Research)
Feb-16-23 08:00AM	GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +19.41%
Feb-15-23 08:00AM	GlycoMimetics Announces Continuation of Phase 3 Study of E-selectin Antagonist Uproleselan in Relapsed/Refractory AML to Originally Planned Final Analysis Following Interim Analysis by Independent Data Monitoring Committee (Business Wire) -62.47%
Feb-14-23 06:23AM	Daily Vickers Top Buyers & Sellers for 02/14/2023 (Argus Research) +7.14%
Feb-06-23 07:00AM	GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Jan-22-23 07:30AM	This Small Pharma Company Could Develop Into a Nice Trade (TheStreet.com)
07:24AM	GlycoMimetics, Inc.'s (NASDAQ:GLYC) Shift From Loss To Profit (Simply Wall St.)
Dec-30-22 07:17AM	Daily Vickers Top Insider Picks for 12/30/2022 (Argus Research)
Dec-28-22 06:58AM	Daily Vickers Top Buyers & Sellers for 12/28/2022 (Argus Research) +19.20%
Dec-26-22 07:14AM	Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Invest In Growth? (Simply Wall St.)
Dec-19-22 09:40AM	Is Axonics (AXNX) Outperforming Other Medical Stocks This Year? (Zacks)
Dec-12-22 07:00AM	GlycoMimetics Announces New Uproleselan Clinical Data in Both Frontline Unfit and Treated Secondary Acute Myeloid Leukemia presented at ASH Annual Meeting (Business Wire)
Dec-02-22 01:18PM	Individual investors account for 44% of GlycoMimetics, Inc.'s (NASDAQ:GLYC) ownership, while hedge funds account for 18% (Simply Wall St.) +7.01%
09:40AM	Is GlycoMimetics (GLYC) Outperforming Other Medical Stocks This Year? (Zacks)
Nov-23-22 09:55AM	After Golden Cross, GlycoMimetics (GLYC)'s Technical Outlook is Bright (Zacks)
Nov-16-22 09:40AM	Are Medical Stocks Lagging Axonics (AXNX) This Year? (Zacks) +9.41%
Nov-12-22 07:14AM	GlycoMimetics Third Quarter 2022 Earnings: US$0.16 loss per share (vs US$0.34 loss in 3Q 2021) (Simply Wall St.)
Nov-10-22 09:12AM	Insiders at GlycoMimetics, Inc. (NASDAQ:GLYC) recouped some losses this week after buying this year, still down US$49k (Simply Wall St.) +19.48%
Nov-09-22 07:00AM	GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2022 (Business Wire) +19.32%
Nov-08-22 04:05PM	GlycoMimetics to Participate in Two Upcoming Investor Conferences (Business Wire)
Nov-03-22 09:00AM	GlycoMimetics Announces New Uproleselan Clinical Data in Both Frontline Unfit and Treated Secondary Acute Myeloid Leukemia Will Be Presented at ASH Annual Meeting (Business Wire)

GlycoMimetics, Inc. engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Invus Public Equities, L.P.	10% Owner	Aug 08 '24	Sale	0.19	260,873	50,009	6,317,565	Aug 09 04:30 PM
Invus Public Equities, L.P.	10% Owner	Aug 07 '24	Sale	0.18	61,488	11,197	6,578,438	Aug 09 04:30 PM
Invus Public Equities, L.P.	10% Owner	Aug 05 '24	Sale	0.19	164,523	30,996	6,695,658	Aug 07 04:30 PM
Invus Public Equities, L.P.	10% Owner	Aug 06 '24	Sale	0.18	55,732	10,188	6,639,926	Aug 07 04:30 PM
Invus Public Equities, L.P.	10% Owner	Aug 02 '24	Sale	0.20	286,200	57,354	6,860,181	Aug 05 04:53 PM
Invus Public Equities, L.P.	10% Owner	Aug 01 '24	Sale	0.22	63,564	13,743	7,146,381	Aug 05 04:53 PM
Invus Public Equities, L.P.	10% Owner	Jul 30 '24	Sale	0.22	756,835	167,185	7,209,945	Jul 30 05:16 PM
Invus Public Equities, L.P.	10% Owner	Jul 29 '24	Sale	0.24	363,949	85,637	7,966,780	Jul 30 05:16 PM
Invus Public Equities, L.P.	10% Owner	Jul 26 '24	Sale	0.24	258,335	62,440	8,330,729	Jul 30 05:16 PM
Rock Edwin	Chief Medical Officer	Jun 20 '24	Buy	0.25	190,000	48,108	565,403	Jun 24 04:29 PM
Rock Edwin	Chief Medical Officer	Jun 21 '24	Buy	0.27	115,000	30,716	680,403	Jun 24 04:29 PM
Hahn Brian M.	SVP Finance, CFO	Jun 18 '24	Buy	0.25	17,500	4,335	70,643	Jun 20 04:15 PM
Rock Edwin	Chief Medical Officer	Sep 21 '23	Buy	1.38	35,000	48,300	345,000	Sep 25 04:21 PM
Rock Edwin	Chief Medical Officer	Sep 22 '23	Buy	1.38	30,403	41,956	375,403	Sep 25 04:21 PM

Open in Screener

ACLX

Arcellx Inc

Sep 06 • 04:00PM ET

71.25

Dollar change +0.88
Percentage change 1.25	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: IWM VTI XBI VXF IWO IBB SCHA VTWO VHT LABU

Index	RUT	P/E	-	EPS (ttm)	-1.08	Insider Own	25.04%	Shs Outstand	52.28M	Perf Week	5.59%
Market Cap	3.83B	Forward P/E	-	EPS next Y	-2.33	Insider Trans	-5.55%	Shs Float	40.29M	Perf Month	39.95%
Income	-53.89M	PEG	-	EPS next Q	-0.33	Inst Own	81.58%	Short Float	12.48%	Perf Quarter	38.78%
Sales	144.75M	P/S	26.46	EPS this Y	0.14%	Inst Trans	15.14%	Short Ratio	11.15	Perf Half Y	0.68%
Book/sh	9.08	P/B	7.84	EPS next Y	-58.49%	ROA	-7.94%	Short Interest	5.03M	Perf Year	92.83%
Cash/sh	9.61	P/C	7.41	EPS next 5Y	-	ROE	-13.80%	52W Range	30.88 - 75.10	Perf YTD	28.38%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-29.89%	ROI	-10.07%	52W High	-5.13%	Beta	0.25
Dividend TTM	-	Quick Ratio	6.01	Sales past 5Y	0.00%	Gross Margin	97.77%	52W Low	130.73%	ATR (14)	3.29
Dividend Ex-Date	-	Current Ratio	6.01	EPS Y/Y TTM	73.62%	Oper. Margin	-55.73%	RSI (14)	63.32	Volatility	5.66% 4.90%
Employees	130	Debt/Eq	0.15	Sales Y/Y TTM	349.32%	Profit Margin	-37.23%	Recom	1.12	Target Price	80.14
Option/Short	Yes / Yes	LT Debt/Eq	0.10	EPS Q/Q	-2.50%	Payout	-	Rel Volume	1.24	Prev Close	70.37
Sales Surprise	24.27%	EPS Surprise	1.72%	Sales Q/Q	91.47%	Earnings	Aug 08 AMC	Avg Volume	450.94K	Price	71.25
SMA20	9.01%	SMA50	16.20%	SMA200	21.33%	Trades		Volume	561,401	Change	1.25%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-03-24	Initiated	Cantor Fitzgerald	Overweight
May-31-24	Initiated	Piper Sandler	Overweight	$70
Mar-07-24	Initiated	Morgan Stanley	Overweight	$81
Jan-04-24	Reiterated	Needham	Buy	$65 → $71
Dec-19-23	Initiated	Scotiabank	Sector Outperform	$66
Oct-30-23	Initiated	TD Cowen	Outperform
Oct-17-23	Initiated	UBS	Buy	$52
May-18-23	Initiated	Truist	Buy	$60
Apr-14-23	Initiated	Robert W. Baird	Outperform	$39
Mar-14-23	Initiated	Stifel	Buy	$43
Feb-13-23	Initiated	H.C. Wainwright	Buy	$42
Dec-13-22	Resumed	BofA Securities	Buy	$29 → $37
Oct-31-22	Initiated	Guggenheim	Buy	$36
Oct-27-22	Initiated	Needham	Buy	$31
Jul-20-22	Initiated	Canaccord Genuity	Buy	$32
Mar-01-22	Initiated	SVB Leerink	Outperform	$47
Mar-01-22	Initiated	BofA Securities	Buy	$24

Show Previous Ratings

Aug-08-24 05:25PM	Arcellx, Inc. (ACLX) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +12.31%
04:00PM	Arcellx Provides Second Quarter 2024 Financial Results and Business Updates (Business Wire)
Aug-02-24 06:53AM	Heres Why Arcellx (ACLX) Slipped in Q2 (Insider Monkey) -5.69%
Jul-04-24 02:13PM	FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals (InvestorPlace)
Jun-29-24 03:08AM	Insider Sale: CFO Michelle Gilson Sells 12,877 Shares of Arcellx Inc (ACLX) (GuruFocus.com)
04:42PM	Loading…
Jun-21-24 04:42PM	Arcellx Stock Earns Relative Strength Rating Upgrade (Investor's Business Daily)
May-27-24 12:32PM	7 Biotech Stocks to Put on Your Breakthrough Radar (InvestorPlace)
May-25-24 03:11AM	Insider Sale: CFO Michelle Gilson Sells Shares of Arcellx Inc (ACLX) (GuruFocus.com)
May-17-24 08:06AM	Private Equity Prowl: 3 Overlooked Stocks Primed for Buyout Bids (InvestorPlace)
May-15-24 07:21AM	Stifel Adjusts Price Target on Arcellx to $83 From $82, Maintains Buy Rating (MT Newswires)
May-14-24 08:00AM	Evercore ISI Starts Arcellx With Outperform Rating (MT Newswires)
May-10-24 01:13PM	Arcellx Inc (ACLX) Q1 2024 Earnings: Narrower Losses and Revenue Surge (GuruFocus.com) -5.67%
04:21AM	Kite and Arcellx prepare to launch Phase III multiple myeloma trial (Clinical Trials Arena)
May-09-24 10:57PM	ACLX Stock Earnings: Arcellx Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:10PM	Arcellx, Inc. (ACLX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Loading…
04:05PM	Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program (Business Wire)
04:05PM	Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program (Business Wire)
04:00PM	Arcellx Provides First Quarter 2024 Financial Results (Business Wire)
06:49AM	Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine (InvestorPlace)
May-07-24 04:00PM	Arcellx to Participate in Two Upcoming Investor Conferences (Business Wire)
May-03-24 05:57PM	Arcellx Insider Sold Shares Worth $932,557, According to a Recent SEC Filing (MT Newswires)
Apr-23-24 11:26AM	Should You Be Bullish on Arcellx (ACLX)? (Insider Monkey)
Apr-04-24 04:00PM	Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference (Business Wire)
08:40AM	How Arcellx (ACLX) Stock Stands Out in a Strong Industry (Zacks)
Mar-29-24 02:57PM	Dell, Dun & Bradstreet, Diebold Nixdorf, and More Stocks See Action From Activist Investors (Barrons.com)
Mar-28-24 08:13AM	Insiders Are Dumping These 10 Healthcare Stocks (Insider Monkey)
Mar-27-24 01:50AM	Insider Sell: Arcellx Inc's Chief Medical Officer Christopher Heery Disposes of 46,815 Shares (GuruFocus.com)
Mar-20-24 04:00PM	Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference (Business Wire)
Feb-29-24 04:00PM	Arcellx to Participate at the TD Cowen 44th Annual Health Care Conference (PR Newswire)
Feb-28-24 07:30PM	Arcellx, Inc. (ACLX) Q4 Earnings and Revenues Surpass Estimates (Zacks)
04:00PM	Loading…
04:00PM	Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights (PR Newswire)
Feb-15-24 11:57AM	The 3 Biotech Stocks That Could Make Your February Unforgettable (InvestorPlace)
Jan-16-24 01:51PM	Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market (InvestorPlace)
Dec-22-23 01:30AM	Chief Medical Officer Christopher Heery Sells 120,000 Shares of Arcellx Inc (GuruFocus.com)
Dec-15-23 05:04PM	Pharmas Frontline: 3 Stocks Driving Revolutionary Drug Development (InvestorPlace)
Dec-08-23 04:00PM	Arcellx Announces Continued Robust Long-Term Responses from Its CART-ddBCMA (anito-cel) Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at ASH (PR Newswire) -6.87%
Nov-30-23 09:37PM	3 Biotech Stocks That Could Be Multibaggers in the Making (InvestorPlace)
Nov-21-23 08:00AM	These Stocks Are Exploding In The November Stock Market Rally (Investor's Business Daily)
Nov-16-23 10:10AM	Arcellx (ACLX) Up 5% on Partnership Expansion With Gilead (Zacks)
Nov-15-23 04:05PM	Arcellx, A Top 2% Stock, Breaks Out After Inking A $285 Million Deal With Gilead (Investor's Business Daily) +5.31%
09:47AM	Arcellx Stock Surges as Gilead Adds to Stake, Expands Collaboration (Barrons.com)
09:22AM	Gilead hands Arcellx $285M to expand BCMA cell therapy deal, sparking fresh push for congested market (FierceBiotech.com)
07:16AM	Gilead expands Arcellx cancer cell therapy deal (BioPharma Dive)
06:00AM	Kite and Arcellx Announce Expansion in Strategic Partnership (Business Wire)
06:00AM	ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP (PR Newswire)
Nov-13-23 04:47PM	Arcellx Inc (ACLX) Reports Q3 2023 Financial Results and Business Updates (GuruFocus.com)
04:00PM	Arcellx Provides Third Quarter 2023 Financial Results and Business Highlights (PR Newswire)
Nov-09-23 11:14AM	There Were 181 IPOs In 2022: $1K In Either Of These Two Would Have You Up 200%+ (Benzinga)
08:30AM	Is a Surprise Coming for Arcellx (ACLX) This Earnings Season? (Zacks)
Nov-02-23 09:40AM	Are Medical Stocks Lagging Arcellx (ACLX) This Year? (Zacks) +18.55%
09:00AM	Arcellx Announces Oral Presentation for Its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 65th ASH Annual Meeting and Exposition (PR Newswire)
Oct-26-23 04:00PM	Arcellx to Participate in Two Upcoming Investor Conferences (PR Newswire)
Oct-23-23 02:50AM	7 Biotech Stocks to Get In Now Before Investors Catch On (InvestorPlace)
Oct-17-23 09:40AM	Is Arcellx (ACLX) Stock Outpacing Its Medical Peers This Year? (Zacks)
Sep-29-23 12:43PM	25 Biggest Stocks with Negative Beta (Insider Monkey)
Sep-04-23 09:55AM	Wall Street Analysts Believe Arcellx, Inc. (ACLX) Could Rally 35.56%: Here's is How to Trade (Zacks)
Sep-01-23 09:18AM	5 Biotech Stocks to Buy as New Drug Approvals Drive Industry Prospects (Zacks)
Aug-17-23 09:55AM	Does Arcellx, Inc. (ACLX) Have the Potential to Rally 39.12% as Wall Street Analysts Expect? (Zacks)
Aug-16-23 01:21PM	Gilead (GILD), Tentarix To Develop Cancer, Inflammation Therapies (Zacks)
Aug-14-23 04:00PM	Arcellx Announces Partial Clinical Hold Lifted on iMMagine-1 Phase 2 Clinical Program and Reports Second Quarter Financial Results (PR Newswire) +6.62%
Jul-31-23 07:13AM	Arcellx's (NASDAQ:ACLX) investors will be pleased with their respectable 51% return over the last year (Simply Wall St.)
Jul-25-23 02:37AM	Should You be Bullish on Arcellx (ACLX)? (Insider Monkey)
Jun-26-23 12:48PM	Gilead (GILD) Breast Cancer Drug Gets Positive CHMP Opinion (Zacks)
Jun-22-23 11:04AM	Biotech Stock Roundup: DICE Gains on LLY Buyout, MRSN Down on Update & More (Zacks)
Jun-21-23 10:38AM	Arcellx (RCLX) Down on Hold for Lead Program CART-ddBCMA (Zacks)
Jun-20-23 04:05PM	Arcellx, A Top 5% Biotech, Dives After A 'Perfect Storm' Leads To A Patient's Death (Investor's Business Daily) -7.18%
Jun-19-23 07:46PM	Arcellx Announces Clinical Hold for its iMMagine-1 Phase 2 Clinical Program (PR Newswire)
May-11-23 10:45AM	Top Small-Cap Stocks for May 2023 (Investopedia)
May-10-23 06:11AM	Results: Arcellx, Inc. Delivered A Surprise Loss And Now Analysts Have New Forecasts (Simply Wall St.)
May-08-23 05:15PM	Arcellx, Inc. (ACLX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:00PM	Arcellx Provides First Quarter Financial Results (PR Newswire)
May-04-23 04:59AM	Zacks.com featured highlights Arcellx, Harrow Health, PROG, Chipotle Mexican Grill and Meta (Zacks)
May-03-23 06:44AM	5 Stocks With Recent Price Strength That Still Have Upside (Zacks)
Apr-28-23 03:34PM	Gilead Sciences (GILD) Q1 2023 Earnings Call Transcript (Motley Fool)
Apr-25-23 12:00PM	Arcellx, Inc. (ACLX) is a Great Momentum Stock: Should You Buy? (Zacks)
Apr-21-23 12:00PM	Arcellx, Inc. (ACLX) Upgraded to Strong Buy: Here's What You Should Know (Zacks) +8.50%
Apr-13-23 04:01PM	Arcellx to Participate at the Canaccord Genuity 2023 Horizons in Oncology Virtual Conference (PR Newswire) +5.84%
Apr-11-23 10:00AM	Best Momentum Stocks to Buy for April 11th (Zacks)
Apr-05-23 09:55AM	Wall Street Analysts Predict a 29.58% Upside in Arcellx, Inc. (ACLX): Here's What You Should Know (Zacks)
Apr-04-23 12:20PM	Earnings Estimates Moving Higher for Arcellx, Inc. (ACLX): Time to Buy? (Zacks)
Apr-03-23 08:34AM	Do Options Traders Know Something About Arcellx (ACLX) Stock We Don't? (Zacks)
Mar-29-23 05:25PM	Arcellx, Inc. (ACLX) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Arcellx Provides Fourth Quarter and Year-End 2022 Financial Results and Business Highlights (PR Newswire)
Mar-16-23 12:18PM	Is a Surprise Coming for Arcellx (ACLX) This Earnings Season? (Zacks)
Feb-21-23 04:00PM	Arcellx to Participate at the H.C. Wainwright Cell Therapy Virtual Conference (PR Newswire) -5.09%
Feb-02-23 04:00PM	Arcellx to Participate in Upcoming Investor Conferences (PR Newswire)
Jan-30-23 09:00AM	Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma (Business Wire)
Jan-04-23 11:45AM	Gilead's (GILD) Application for Trodelvy Gets EMA Validation (Zacks)
Dec-14-22 10:24AM	Biotech Stock Roundup: HZNP Surges on AMGN Offer, TRDA Gains on VRTX Deal & More (Zacks)
Dec-12-22 10:55AM	Gilead (GILD) Partners With Arcellx, ImmunoGen in Oncology (Zacks)
Dec-09-22 04:08PM	Top-Notch IPO Stock Arcellx Breaks Out On $325 Million Cancer Tie-Up With Gilead Sciences (Investor's Business Daily) +29.24%
09:54AM	Arcellx Stock Surges on Multiple Myeloma Treatment Collaboration With Gilead (Barrons.com)
09:42AM	Gilead's Kite, Arcellx Ink Over $300M Collaboration Pact For Late-Stage Multiple Myeloma Candidate (Benzinga)
08:46AM	Gilead to co-develop Arcellx's multiple myeloma drug (MarketWatch)
08:17AM	Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma (Business Wire)
08:17AM	Arcellx Announces Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma and Additional Pipeline Progress (PR Newswire)
08:15AM	Arcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple Myeloma (PR Newswire)
Nov-30-22 11:08AM	We're Hopeful That Arcellx (NASDAQ:ACLX) Will Use Its Cash Wisely (Simply Wall St.)
Nov-14-22 04:00PM	Arcellx Reports Third Quarter 2022 Financial Results and Business Progress (PR Newswire)
01:13PM	The bear market rally has more room to run, Guggenheim says. Here are 2 stocks to bet on (TipRanks)

Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Gaithersburg, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Heery Christopher	CHIEF MEDICAL OFFICER	Sep 05 '24	Option Exercise	15.00	3,421	51,315	12,699	Sep 06 05:48 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Sep 05 '24	Sale	70.02	3,421	239,526	9,278	Sep 06 05:48 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Sep 03 '24	Option Exercise	13.27	27,451	364,232	36,729	Sep 03 09:33 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Sep 03 '24	Sale	67.03	27,451	1,840,053	9,278	Sep 03 09:33 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Aug 26 '24	Option Exercise	15.00	21,684	325,260	30,962	Aug 28 04:54 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Aug 26 '24	Sale	71.12	21,684	1,542,274	9,278	Aug 28 04:54 PM
CHRISTOPHER HEERY	Officer	Aug 26 '24	Proposed Sale	69.38	48,907	3,393,168		Aug 26 04:24 PM
Patel Kavita	Director	Aug 20 '24	Option Exercise	6.66	1,500	9,990	1,500	Aug 22 04:01 PM
Patel Kavita	Director	Aug 20 '24	Sale	65.88	1,500	98,820	0	Aug 22 04:01 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Aug 16 '24	Option Exercise	6.28	5,450	34,226	14,728	Aug 19 04:39 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Aug 16 '24	Sale	65.05	5,450	354,526	9,278	Aug 19 04:39 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Aug 01 '24	Option Exercise	10.94	20,000	218,764	29,278	Aug 02 04:02 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Aug 01 '24	Sale	60.42	20,000	1,208,435	9,278	Aug 02 04:02 PM
Patel Kavita	Director	Jul 30 '24	Option Exercise	6.66	1,500	9,990	1,500	Aug 01 05:24 PM
Patel Kavita	Director	Jul 30 '24	Sale	61.97	1,500	92,949	0	Aug 01 05:24 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jul 16 '24	Option Exercise	6.28	10,901	68,458	20,179	Jul 18 06:44 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jul 16 '24	Sale	65.30	10,901	711,854	9,278	Jul 18 06:44 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jul 11 '24	Option Exercise	6.28	3,671	23,054	12,949	Jul 12 06:39 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jul 12 '24	Option Exercise	6.28	1,780	11,178	11,058	Jul 12 06:39 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jul 11 '24	Sale	60.01	3,671	220,302	9,278	Jul 12 06:39 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jul 12 '24	Sale	60.21	1,780	107,175	9,278	Jul 12 06:39 PM
Patel Kavita	Director	Jul 09 '24	Option Exercise	6.66	1,500	9,990	1,500	Jul 11 04:04 PM
Patel Kavita	Director	Jul 09 '24	Sale	56.63	1,500	84,947	0	Jul 11 04:04 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jul 01 '24	Option Exercise	11.93	20,000	238,646	29,278	Jul 03 04:05 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jul 01 '24	Sale	55.39	20,000	1,107,763	9,278	Jul 03 04:05 PM
Patel Kavita	Director	Jun 27 '24	Option Exercise	6.66	10,000	66,600	10,000	Jun 28 04:08 PM
Patel Kavita	Director	Jun 27 '24	Sale	54.27	10,000	542,656	0	Jun 28 04:08 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	Jun 26 '24	Sale	53.70	12,877	691,519	6,915	Jun 28 04:06 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jun 12 '24	Option Exercise	11.53	20,000	230,554	29,278	Jun 14 04:31 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jun 12 '24	Sale	55.13	20,000	1,102,668	9,278	Jun 14 04:31 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	May 23 '24	Option Exercise	0.00	22,428	0	31,913	May 24 08:16 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	May 24 '24	Sale	50.71	12,121	614,656	19,792	May 24 08:16 PM
Heery Christopher	CHIEF MEDICAL OFFICER	May 01 '24	Option Exercise	6.28	18,168	114,095	27,106	May 03 05:50 PM
Heery Christopher	CHIEF MEDICAL OFFICER	May 01 '24	Sale	51.33	18,168	932,557	8,938	May 03 05:50 PM
Ware Olivia C	Director	Apr 16 '24	Option Exercise	7.61	9,402	71,549	9,402	Apr 18 04:01 PM
Ware Olivia C	Director	Apr 16 '24	Sale	55.55	9,402	522,260	0	Apr 18 04:01 PM
Elghandour Rami	SEE REMARKS	Apr 01 '24	Sale	67.09	23,086	1,548,887	69,253	Apr 03 04:44 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Mar 22 '24	Option Exercise	6.28	20,000	125,600	50,303	Mar 26 08:52 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Mar 26 '24	Option Exercise	6.28	5,450	34,226	14,388	Mar 26 08:52 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Mar 22 '24	Sale	70.18	41,365	2,903,066	8,938	Mar 26 08:52 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Mar 26 '24	Sale	69.11	5,450	376,648	8,938	Mar 26 08:52 PM
Carroll Jill	Director	Mar 21 '24	Sale	70.55	504,263	35,575,755	1,479,148	Mar 25 05:30 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	Mar 18 '24	Sale	69.34	6,825	473,255	9,485	Mar 18 08:49 PM
Ware Olivia C	Director	Mar 15 '24	Option Exercise	7.61	9,000	68,490	9,000	Mar 18 06:38 PM
Ware Olivia C	Director	Mar 15 '24	Sale	70.40	9,000	633,582	0	Mar 18 06:38 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Feb 09 '24	Sale	63.40	3,688	233,811	33,270	Feb 12 07:46 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Feb 08 '24	Sale	62.29	3,456	215,290	36,958	Feb 12 07:46 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Feb 12 '24	Sale	64.46	2,967	191,251	30,303	Feb 12 07:46 PM
Elghandour Rami	SEE REMARKS	Feb 09 '24	Sale	63.40	13,886	880,340	103,508	Feb 12 07:43 PM
Elghandour Rami	SEE REMARKS	Feb 08 '24	Sale	62.29	13,010	810,451	117,394	Feb 12 07:43 PM
Elghandour Rami	SEE REMARKS	Feb 12 '24	Sale	64.46	11,169	719,948	92,339	Feb 12 07:43 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Feb 07 '24	Option Exercise	0.00	22,555	0	40,414	Feb 09 04:08 PM
Elghandour Rami	SEE REMARKS	Feb 07 '24	Option Exercise	0.00	70,211	0	130,404	Feb 09 04:05 PM
Heery Christopher	Chief Medical Officer	Jan 04 '24	Sale	55.27	7,598	419,926	17,859	Jan 08 04:06 PM
Gilson Michelle	Chief Financial Officer	Jan 04 '24	Sale	55.27	8,514	470,551	16,310	Jan 08 04:04 PM
Elghandour Rami	See Remarks	Jan 04 '24	Sale	55.27	29,073	1,606,804	60,193	Jan 08 04:02 PM
Heery Christopher	Chief Medical Officer	Jan 03 '24	Option Exercise	0.00	16,519	0	25,457	Jan 04 07:32 PM
Elghandour Rami	See Remarks	Jan 03 '24	Option Exercise	0.00	53,097	0	89,266	Jan 04 07:29 PM
Heery Christopher	Chief Medical Officer	Dec 18 '23	Option Exercise	6.28	120,000	753,600	127,795	Dec 19 04:43 PM
Heery Christopher	Chief Medical Officer	Dec 18 '23	Sale	50.17	120,000	6,020,281	7,795	Dec 19 04:43 PM
Carroll Jill	Director	Dec 14 '23	Sale	49.13	504,263	24,774,441	1,983,411	Dec 18 04:47 PM

KRRO

Korro Bio Inc.

NET

Cloudflare Inc

SVRA

Savara Inc

GLYC

GlycoMimetics Inc

ACLX

Arcellx Inc

Upgrade your FINVIZ experience